Vitality Watch

⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.

Mentioned 1× · first seen 04-oct-2026 · last seen 04-oct-2026

Bispecific T-Cell Engager Senolytics (uPAR-GFD-CD3)

Current understanding

Bispecific T-cell engagers (BiTEs) directed at senescent-cell surface antigens — notably a uPAR-targeting GFD-CD3 construct — are being proposed as a dose-titratable, ‘off-the-shelf’ alternative to senolytic CAR T cells. The lead preclinical package reports senescent-cell clearance and alleviation of age-related pathologies in aged mice and non-human primates, with serum aminotransferase activity used as a titration/safety biomarker [animal-model]. No human aging data; oncology-derived cytokine release and on-target/off-target toxicity concerns carry over, as do questions about durability of effect compared with cell-based approaches [expert-opinion].

Evidence log

Open questions

Related

Contributing findings

pubmed preclinical
uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
01-oct-2026 novelty 4 per-area 4 introduces
rss preclinical animal-model
uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor
29-sep-2026 novelty 4 per-area 4 strengthens

build build 880 · 2bcef25 · 2026-11-18